Connect your AI

CARL CARL Accrued Liabilities, Current

Accrued Liabilities, Current at other companies

Johnson & JohnsonJNJ

——

Globus MedicalGMED

——

3D SystemsDDD

——

SI-BONE, Inc.SIBN

——

IAR

Integra LifeSciencesIART

——

BioventusBVS

——

Other financials

Income statement

Revenue$16.1M+58.2%

Gross profit$12.4M+62.7%

Operating income-$9.3M-62.2%

Net income-$8.7M-51.8%

EPS (diluted)-$0.32+78.2%

Balance sheet

Cash & equivalents$73.0M+68.1%

Total debt$17.3M—

Total equity$92.2M+220%

Total assets$118.8M—

Cash flow

Operating cash flow-$13.0M-59.5%

CapEx$79.0K-4.8%

Free cash flow-$13.1M-58.8%

Valuation

Market cap$305.56M-20.3%

Enterprise value$249.8M—

P/S5.4×—

Profitability

Gross margin75.9%+1.4pp

Operating margin-60.5%-10.2pp

Net margin-57.8%-11.2pp

FCF margin-61.1%—

Returns & leverage

Return on equity-416.9%—

Debt / equity0.2×—

Current ratio11.9×—

Where this comes from

Reported directly by CARL in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: CARL’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about CARL's accrued liabilities, current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is CARL's accrued liabilities, current?: CARL (CARL) reported accrued liabilities, current of $3.2M in Q1 2026.